Compare GSK plc (GSK) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs uniQure N.V. Ordinary Shares — how do they compare? GSK plc trades at $48.54 (market cap $92.78B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: GSK plc is far larger — about 62.7× uniQure N.V. Ordinary Shares's market cap, and GSK plc pays a 3.92% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| GSK | QURE | |
|---|---|---|
Market Cap | $92.78B | $1.48B |
Volume | 5,756,402 | 2,488,780 |
Sector | Health | Health |
52-Week High | $61.18 | $70.59 |
52-Week Low | $43.24 | $9.03 |
Typical Hold Time | 93 Days | 0 Days |
Enterprise Value | $112.77B | $728.62M |
Dividend Yield | 3.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.87, up 2.02% today, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 72.73% gross margins and 14.52% net income margin, supported by consistent revenue growth from $32.67B in 2025. Recent developments include a $750M cancer therapy acquisition and strategic focus on oncology expansion.
GSK presents a mixed outlook with solid fundamentals and strategic pipeline investments offset by technical weakness and patent cliff concerns. The stock offers value at 14.84 P/E but faces execution risks in oncology growth and HIV patent expirations. Analyst consensus leans cautious with 55% hold ratings.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
